

RP00017

Leader in Biomolecular Solutions for Life Science



# Recombinant Human VEGF-A/VEGF121(K321N) Protein

Catalog No.: RP00017

Recombinant

## Sequence Information

Species	Gene ID	Swiss Prot
Human	7422	P15692

### Tags

No tag

### Synonyms

VEGFA; MVCD1; VEGF; VPF; vascular endothelial growth factor A; MVCD1; VEGF; VPF; L VEGFA; VEGF A

## Product Information

Source	Purification
<I>E. coli</I>	> 97% by SDS-PAGE.

### Endotoxin

< 1.0 EU/μg of the protein by LAL method.

### Formulation

Lyophilized from a 0.22 μm filtered solution of 20mM Tris, 100mM NaCl, pH 8.0. Contact us for customized product form or formulation.

### Reconstitution

Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stabilizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize freeze-thaw cycles.

## Background

This protein is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This protein is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome.

## Basic Information

### Description

Recombinant Human VEGF-A/VEGF121(K321N) Protein is produced by <I>E. coli</I> expression system. The target protein is expressed with sequence (Ala207-Arg327 (Lys321Asn)) of human VEGF121 (Accession #NP\_001020541.2).

### Bio-Activity

1. Measured by its binding ability in a functional ELISA. Immobilized Human VEGF121 at 2 μg/mL (100 μL/well) can bind Human KDR with a linear range of 0.2-10 ng/mL. 2. Measured in a cell proliferation assay using human umbilical vein endothelial cells (HUVEC). The ED<sub>50</sub> for this effect is typically 0.017-0.068 ng/mL, corresponding to a specific activity of 1.47 ×10<sup>7</sup>-5.88 ×10<sup>7</sup> units/mg.

### Storage


Store the lyophilized protein at -20°C to -80 °C for long term. After reconstitution, the protein solution is stable at -20 °C for 3 months, at 2-8 °C for up to 1 week. Avoid repeated freeze/thaw cycles.

## Contact




[www.abclonal.com](http://www.abclonal.com)


## Validation Data



Recombinant Human VEGF-A/VEGF121(K321N) Protein was determined by SDS-PAGE with Coomassie Blue, showing a band at 18 kDa.



Immobilized Recombinant Human VEGF121 at 2 µg/mL (100 µL/well) can bind Human KDR with a linear range of 0.2-10 ng/mL.



Recombinant Human VEGFA stimulates cell proliferation of the human umbilical vein endothelial cells (HUVEC). The ED<sub>50</sub> for this effect is typically 0.017-0.068 ng/mL, corresponding to a specific activity of 1.47 × 10<sup>7</sup>-5.88 × 10<sup>7</sup> units/mg.